AAV-aibp therapy for alzheimer's disease

Ended Project Grant Awarded Last action

Award ID
R41AG081004
Recipient
Awarding agency
Obligated
$994,112

Award facts

Assistance listing
93.866 Aging Research
Completion date
Originally
Place of performance
California, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Therapy for alzheimer's disease and related dementias (ad/adrd), slow-progressing neurodegenerative diseases, remains elusive. Therapeutic approaches focusing on beta amyloid (ASS) removal from the brain or on targeting genes for which strong associations between their polymorphism and ad/adrd are established, have had a mixed record of success. We propose a novel strategy to reverse ad/adrd associated neuroinflammation and mitochondrial dysfunction via targeting pathological lipid rafts in inflammatory and activated cells. These cholesterol-rich plasma membrane structures become stable and enlarged to host the assembly of many inflammatory receptors and other molecules involved in pathological processes leading to neuronal cell death and neurodegeneration. We have identified apoa-i binding protein (aibp, encoded by APOA1BP gene) as a key regulator of cellular cholesterol metabolism, which can selectively target pathological lipid rafts via its binding to TLR4, without damaging physiological lipid rafts. In preliminary studies, the APOA1BP-/- mice crossed with APP/PS1 transgenic mice presented more ASS plaques, an exacerbated dysfunctional microglia phenotype and increased neuronal cell death when compared to APP/PS1 mice. In addition, mitochondria in the brain of aibp- deficient APP/PS1 mice were morphologically distorted, with a characteristic hyper-branched and cupped shape, typically associated with oxidative stress. The adeno-associated virus (AAV)-mediated overexpression of a secreted form of aibp in the brain of APOA1BP-/- APP/PS1 mice restored the microglial homeostatic phenotype. Raft pharmaceuticals proposes the development of an AAV-aibp based therapy to provide effective neuroprotection in ad/adrd. Specifically in this phase 1 sttr project, we propose to construct and optimize an AAV-aibp vector (RFT1041), which will be used in efficacy studies of aim 2 and is expected to enter IND- enabling development for human clinical applications. We will explore intracranial and intrathecal routes of delivery and test if a single AAV-aibp injection achieves sustained aibp expression in the brain. The efficacy of RFT1041 (3 different doses) will be tested in APP/PS1 and 3XTG mouse models to evaluate survival, changes in memory and learning, the extent of ASS plaques and TAU tangles, microglia activation, synaptotoxicity, neuronal cell death, autophagy, ER stress, and mitochondrial dysfunction. In addition, advanced EM will be used to assess mitochondrial morphology and function. Results of these studies will be used to prepare for and conduct an interact meeting with the FDA to receive preliminary FDA feedback on the proposed development program and assists in minimizing the time spent in product development and reduce time to market.

Transactions

Action Obligated Date
Amendment $0
Amendment $252,944
Amendment $0
Amendment $0
Amendment $0
Amendment $247,056
Amendment $247,056
Original award $247,056

Subawards

Subrecipient Amount Awarded
The Regents Of The University Of California, San Diego Statement of Work STTR “AAV-AIBP therapy for Alzheimer’s disease” The work for this subcontract will be performed in Ju’s laboratory at UC San Diego. Dr. Wonkyu… $290,972

Quick answers

Who received award R41AG081004?

R41AG081004 was awarded to Raft Pharmaceuticals LLC by National Institute on Aging (National Institutes of Health) on September 30, 2022.

How much is award R41AG081004 worth?

$994,112 has been obligated on R41AG081004.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login